VACCINEX, INC. Operating Income Loss

Quick Answer

VACCINEX, INC. reported Operating Income Loss of -$18.74 million for the year ending 2024.

  • VACCINEX, INC. showed an increase of +18.1% in Operating Income Loss from 2023 to 2024.
  • This data is from VACCINEX, INC.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
  • XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2017 to 2024), VACCINEX, INC.'s Operating Income Loss has grown by 11.2%.
  • Historical annual values: Fiscal year 2024: -$18.74 million | Fiscal year 2023: -$22.89 million | Fiscal year 2022: -$19.91 million | Fiscal year 2021: -$22.49 million | Fiscal year 2020: -$28.33 million | Fiscal year 2019: -$32.02 million | Fiscal year 2018: -$27.28 million | Fiscal year 2017: -$21.10 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: